SSRIs for Hot Flashes: Which Ones Work and How Well

Antidepressants that affect serotonin and norepinephrine — the SSRI (selective serotonin reuptake inhibitor) and SNRI (serotonin-norepinephrine reuptake inhibitor) drug classes — turn out to also help regulate the body's temperature control center in the brain, which is disrupted during the estrogen decline of menopause. This makes them a genuine non-hormonal treatment option, not just a way to manage mood alongside hot flashes. They're most often considered by women who can't take hormone therapy due to a history of hormone-sensitive breast cancer, blood clots, or certain other conditions, or who simply prefer not to use hormones. Unlike some non-hormonal supplements, this drug class has a substantial body of randomized, placebo-controlled trial evidence behind it, largely generated through the NIH-funded MsFLASH (Menopause Strategies: Finding Lasting Answers for Symptoms and Health) research network.

Low-dose paroxetine, marketed as Brisdelle at 7.5mg, is the only medication in this class with an FDA approval specifically for moderate-to-severe hot flashes — not as an antidepressant dose, but a lower dose designed to minimize side effects while still calming the brain's temperature regulation. In the trials that supported its approval, paroxetine reduced hot flash frequency by roughly 40-65% compared with about 25-30% for placebo, with women typically noticing improvement within 1-4 weeks. Because it's an SSRI, it's an important one to flag if you're also on tamoxifen for breast cancer treatment — paroxetine can interfere with how tamoxifen is metabolized, so oncologists usually steer patients toward other options in that specific situation, like venlafaxine or escitalopram instead.

Venlafaxine, an SNRI, is one of the most frequently prescribed off-label options for hot flashes and has strong trial support, including MsFLASH studies showing meaningful reductions in both hot flash frequency and severity, often in the range of 55-60% versus roughly 25% with placebo. It's generally considered safe to use alongside tamoxifen, which makes it a common first choice for women with a breast cancer history. Venlafaxine is usually started at a low dose (37.5mg extended-release) and can be increased if needed. Side effects can include nausea, dry mouth, and mild increases in blood pressure at higher doses, so it's typically monitored more closely than paroxetine. If you're navigating menopause symptoms alongside a mood component, this overlaps with broader questions covered in [menopause depression](/blog/menopause-depression-why-risk-peaks-in-perimenopause), since the same medications sometimes address both.

Escitalopram, another SSRI, was also tested in a MsFLASH randomized trial and showed a meaningful reduction in hot flash frequency and severity compared with placebo, along with improvements in sleep quality — a common secondary benefit across this drug class, since better temperature regulation at night often means fewer wake-ups. Citalopram has similar supporting evidence. None of these options work as well, on average, as estrogen-based hormone therapy for hot flash relief, but they're a legitimate, well-studied middle ground for women who need or want a non-hormonal approach and want something more targeted than lifestyle changes or supplements. If you've tried supplement-based approaches first, it's worth comparing what actually has trial evidence — see [black cohosh for hot flashes](/blog/black-cohosh-for-hot-flashes-does-it-actually-work) for how that compares.

The menopause treatment landscape has expanded quickly, and SSRIs/SNRIs now sit alongside newer, more targeted options like the NK3 receptor antagonists fezolinetant (Veozah) and elinzanetant (Lynkuet), which work directly on the brain's temperature-regulating neurons rather than through serotonin pathways broadly. Head-to-head data between these two approaches is still limited, so the right choice often comes down to your specific history: an SSRI/SNRI may be a better fit if you also have anxiety, depression, or a tamoxifen interaction concern with the NK3 antagonists, while the newer drugs may appeal if you want a treatment that isn't a psychiatric medication class. For a closer look at how those newer options compare to each other, see [Lynkuet vs Veozah](/blog/lynkuet-vs-veozah-nonhormonal-hot-flash-pills-compared).